Publications by authors named "L Pantazi"
Article Synopsis
- The study assessed pregnancy outcomes in women with systemic lupus erythematosus (SLE) in Greece, revealing significant risks for complications like foetal loss and prematurity, with 53.7% of pregnancies affected by adverse outcomes.
- SLE patients with antiphospholipid antibodies faced higher risks of foetal issues, while those with low disease activity at pregnancy onset experienced better outcomes; ongoing disease activity and medication use during pregnancy also influenced foetal health.
- The research emphasized the need for careful pregnancy planning and disease management for SLE patients, as flares were common, particularly in the postpartum period and linked to specific symptoms like alopecia and nephritis.
Background: Data regarding the real-life predictors of low disease activity (LDA) in rheumatoid arthritis (RA) patients are limited. Our aim was to evaluate the rate and predictors of LDA and treatment patterns in RA.
Methods: This was a multicenter, prospective, RA cohort study where patients were evaluated in two different time points approximately 12 months apart.
Pregnancy in women with SLE (Systematic Lupus Erythematosus) is considered of "high risk" since it has been related with adverse events both in the mother and the foetus. Many studies have reported relapse of the disease during the pregnancy and the first trimester post-labour, while others have found no difference in terms of frequency and type of relapses. Moreover, adverse obstetrical events like recurrent pregnancy loss, preeclampsia, prematurity, intrauterine growth restriction and neonatal lupus syndrome tend to occur more often in patents with SLE.
View Article and Find Full Text PDFLow disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Semin Arthritis Rheum
December 2018
Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.
Methods: Multicentre prospective observational study of consecutive SLE patients receiving belimumab for at least 3 months, due to active disease refractory to at least one conventional immunosuppressant.
Aim Of The Study: To evaluate the current disease characteristics, treatment and comorbidities of rheumatoid arthritis (RA) in Greece.
Methods: Multicenter, cross-sectional study with a 9-month recruitment period between 2015 and 2016. Demographics, disease characteristics, treatment and comorbidities were collected via a web-based platform.